Table 4.
Differences between mAb and Ligands.
Ligand (PSMA 617) | mAb (J591) |
---|---|
Small (mw 1400) | Large (mw 150,000) |
Short circulation time | Long circulation time (days) |
|
|
Rapidly diffuse to all sites of expression | Mostly target via vasculature |
Toxicities | Toxicities |
|
|